APSR2026-283

Yes
Regular
Submitted
Poster Presentation
 
AP10-005
P05
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1288/1ca37417cd1cbe36178fb36d3b571cbe.pdf
Format: PDF Only
07. COPD
11

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Surya P. Bhatt - University of Alabama at Birmingham Division of Pulmonary, Allergy and Critical Care Medicine Birmingham, AL United States
Guy Brusselle - Ghent University Hospital Department of Respiratory Medicine Ghent Belgium
Helena Backman - Umeå University Department of Public Health and Clinical Medicine, Section of Sustainable Health Umeå Sweden
Alberto Papi - University of Ferrara, S. Anna University Hospital Department of Cardiorespiratory Medicine, Respiratory Medicine Unit Ferrara Italy
Hisatoshi Sugiura - Tohoku University Graduate School of Medicine Department of Respiratory Medicine Sendai, Miyagi Japan
Henrik Watz - Velocity Clinical Research Germany Pulmonology Ahrensburg Germany German Center for Lung Research (DZL) LungenClinic Grosshansdorf, Airway Research Center North (ARCN) Grosshansdorf Germany
Jean Bourbeau - McGill University and Research Institute of the McGill University Health Centre Respiratory Epidemiology and Clinical Research Unit, Department of Medicine Montreal, QC Canada
Paramita Saha-Chaudhuri - Sanofi Specialty Care, Global Medical Affairs / Medical Operations & Excellence Mississauga, ON Canada
Mena Soliman * Regeneron Pharmaceuticals Inc. Global Medical Affairs Tarrytown, NY United States
Jigna Heble - Sanofi Immunology & Inflammation / Respiratory Morristown, NJ United States
Jadwiga A. Wedzicha - Imperial College London Airway Disease Section, National Heart and Lung Institute London United Kingdom
 
 
 
 
Presenting Author Details
Mena
Soliman
mena.soliman@regeneron.com
+31 20 797 1416
31-40
Canada
Original Research
Dupilumab efficacy in reducing exacerbations and symptoms while improving lung function in current and former smokers with COPD and type 2 inflammation
Maximum 25 words
Abstract Content

Medications for chronic obstructive pulmonary disease (COPD) may be less efficacious in active smokers. In BOREAS and NOTUS, dupilumab reduced exacerbations and improved lung function in patients with COPD and type 2 inflammation. This post hoc analysis evaluates dupilumab efficacy in current and former smokers with COPD.

In phase 3 BOREAS (NCT03930732) and NOTUS (NCT04456673), patients with COPD on triple therapy, with moderate-to-severe airflow limitation and type 2 inflammation (screening eosinophils ≥300 cells/µL) received add-on dupilumab 300 mg every 2 weeks or placebo for 52 weeks. Endpoints were: adjusted annualized moderate or severe exacerbation rate, as well as change from baseline in pre-bronchodilator forced expiratory volume in 1 second (pre-bronchodilator FEV1) and Evaluating Respiratory Symptoms in COPD (E-RS:COPD) score by smoking status. Lower E-RS:COPD scores indicate improved symptom control. 

Dupilumab reduced exacerbation relative risk vs placebo by 32% (dupilumab: n=662; placebo: n=654) (relative risk vs placebo: 0.68; 95% CI: 0.57, 0.81; P<0.001) and 31% (dupilumab: n=276; placebo: n=282) (relative risk: 0.69; 95% CI: 0.53, 0.89; P=0.005) in former and current smokers, respectively. At Week 12, dupilumab improved pre-bronchodilator FEV1 in former (LS mean difference vs placebo: 88 mL; 95% CI: 50, 126; P<0.001) and current smokers (64 mL; 95% CI: 19, 109; P=0.005) (interaction P value: 0.36). At Week 52, dupilumab also improved E-RS:COPD scores in former (LS mean difference vs placebo: –0.9 points; 95% CI: –1.5, –0.3; P=0.004) and current smokers (LS mean difference vs placebo: –1.0 points; 95% CI: –2.0, –0.1; P=0.024) (interaction P value: 0.33).

Dupilumab reduced exacerbations and symptom severity while improving lung function in patients with COPD and type 2 inflammation, regardless of smoking status. These findings underscore the potential of dupilumab as an effective treatment, particularly for active smokers with COPD, who depending on geographical area may have limited therapeutic options.  

No
No
 
JPG or JPEG or PNG format ONLY
Smoker, COPD, Exacerbation
maximum 3 keywords and no abbreviations, separated by commas
Research sponsored by Sanofi and Regeneron Pharmaceuticals Inc. ClinicalTrials.gov Identifiers: NCT03930732 and NCT04456673. Medical writing support, under the direction of the authors, was provided by Kimberly Berry, PhD, of the Publications and Medical Affairs Division of Omnicom Health Medical Communications, funded by Sanofi and Regeneron Pharmaceuticals Inc., according to the Good Publication Practice (GPP2022) guidelines.
331